Healthcare provider profile · identity verified

Errol T Buntuyan, MD

Family Practice · WAILUKU, HI · NPI 1316930548

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	506	196
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	282	53
Losartan Potassium	Losartan Potassium	258	99
Lisinopril	Lisinopril	241	91
Amlodipine Besylate	Amlodipine Besylate	236	102
Levothyroxine Sodium	Levothyroxine Sodium	217	74
Rosuvastatin Calcium	Rosuvastatin Calcium	190	80
Trazodone Hcl	Trazodone Hcl	182	66
Gabapentin	Gabapentin	163	68
Tamsulosin Hcl	Tamsulosin Hcl	137	60
Furosemide	Furosemide	126	42
Hydrochlorothiazide	Hydrochlorothiazide	126	48
Omeprazole	Omeprazole	124	47
Atenolol	Atenolol	123	43
Albuterol Sulfate Hfa	Albuterol Sulfate	114	53
Meloxicam	Meloxicam	114	51
Metformin Hcl	Metformin Hcl	106	39
Pantoprazole Sodium	Pantoprazole Sodium	103	37
Zolpidem Tartrate	Zolpidem Tartrate	95	19
Simvastatin	Simvastatin	91	35
Pradaxa	Dabigatran Etexilate Mesylate	82	30
Jardiance	Empagliflozin	78	24
Metoprolol Tartrate	Metoprolol Tartrate	78	30
Allopurinol	Allopurinol	77	32
Metformin Hcl Er	Metformin Hcl	77	35
Tramadol Hcl	Tramadol Hcl	76	16
Terazosin Hcl	Terazosin Hcl	75	29
Finasteride	Finasteride	71	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	67	30
Ibuprofen	Ibuprofen	66	25
Potassium Chloride	Potassium Chloride	60	24
Buspirone Hcl	Buspirone Hcl	57	11
Sertraline Hcl	Sertraline Hcl	57	17
Doxycycline Monohydrate	Doxycycline Monohydrate	56	23
Lorazepam	Lorazepam	56	16
Carvedilol	Carvedilol	54	20
Clopidogrel	Clopidogrel Bisulfate	54	24
Alprazolam	Alprazolam	52	16
Metoprolol Succinate	Metoprolol Succinate	51	18
Montelukast Sodium	Montelukast Sodium	50	20
Pregabalin	Pregabalin	49	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	48	15
Topiramate	Topiramate	47	11
Alendronate Sodium	Alendronate Sodium	46	16
Acyclovir	Acyclovir	44	19
Ezetimibe	Ezetimibe	43	16
Triamcinolone Acetonide	Triamcinolone Acetonide	43	32
Citalopram Hbr	Citalopram Hydrobromide	41	14
Pravastatin Sodium	Pravastatin Sodium	41	12
Testosterone	Testosterone	40	17
Fluoxetine Hcl	Fluoxetine Hcl	39	16
Prednisone	Prednisone	39	25
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	15
Metronidazole	Metronidazole	38	suppressed
Azelastine Hcl	Azelastine Hcl	37	16
Glipizide	Glipizide	37	17
Duloxetine Hcl	Duloxetine Hcl	35	14
Ozempic	Semaglutide	33	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	32	suppressed
Fluticasone Propionate	Fluticasone Propionate	32	11
Humulin N	Insulin Nph Human Isophane	32	11
Spiriva Respimat	Tiotropium Bromide	32	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	31	12
Clonazepam	Clonazepam	30	suppressed
Fenofibrate	Fenofibrate	30	11
Humulin N Kwikpen	Insulin Nph Human Isophane	30	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	27	27
Bisoprolol Fumarate	Bisoprolol Fumarate	27	suppressed
Temazepam	Temazepam	27	suppressed
Alvesco	Ciclesonide	26	13
Bupropion Xl	Bupropion Hcl	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	26	13
Clobetasol Propionate	Clobetasol Propionate	25	suppressed
Eliquis	Apixaban	25	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	11
Mirtazapine	Mirtazapine	24	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	suppressed
Baclofen	Baclofen	21	suppressed
Famotidine	Famotidine	21	suppressed
Terbinafine Hcl	Terbinafine Hcl	21	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Nabumetone	Nabumetone	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Ondansetron Odt	Ondansetron	17	15
Xarelto	Rivaroxaban	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Fluconazole	Fluconazole	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Azithromycin	Azithromycin	15	suppressed
Metolazone	Metolazone	15	suppressed
Morphine Sulfate	Morphine Sulfate	15	suppressed
Morphine Sulfate Er	Morphine Sulfate	15	suppressed
Testosterone Cypionate	Testosterone Cypionate	15	suppressed
Estradiol	Estradiol	14	suppressed
Humulin R	Insulin Regular, Human	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	suppressed
Brilinta	Ticagrelor	13	suppressed
Ciclopirox	Ciclopirox	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Liraglutide	Liraglutide	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Cartia Xt	Diltiazem Hcl	12	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Nystatin	Nystatin	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Lactulose	Lactulose	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error